Detalhe da pesquisa
1.
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
N Engl J Med
; 389(9): 783-794, 2023 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646676
2.
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX).
Blood
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452197
3.
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Eur J Haematol
; 111(4): 544-552, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439123
4.
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Haemophilia
; 28(4): 548-556, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35475308
5.
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Haemophilia
; 27(6): 911-920, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614267
6.
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Haemophilia
; 27(6): 921-931, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636112
7.
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
Blood
; 120(18): 3670-6, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915649
8.
von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease.
Blood Adv
; 8(6): 1405-1414, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237075
9.
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Thromb Haemost
; 121(11): 1400-1408, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581698
10.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Clin Pharmacokinet
; 51(12): 823-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018466